Also, the receptor of advanced glycosylation end products (RAGE) and its soluble form (sRAGE) could be used in cancer diagnosis: patients with breast cancer at high stages show lower sRAGE levels, and these low levels might contribute to disease progression (36). This evidence concerns the gene AGER and breast cancer.